Medicine guide

Brinsupri

Prescription status not stated
Breathing, airways, allergies and cough

Active substance: Brensocatib
Used in: Breathing, airways, allergies and cough
Made by: Insmed Netherlands B.V.
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

From the official label · 2026-09-30 · European Medicines Agency

How it works

From the US prescribing label for the same active substance (Brinsupri). It describes the substance, not this exact product.

Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1).
DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow.

Peak level after1.0–1.4 h

Half-life25–39 h

Mostly cleared after≈ 7 daysfive half-lives — our arithmetic

The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

How the body breaks it down

Brensocatib is primarily metabolized by CYP3A and to a lesser extent by CYP2C8 and CYP2D6.

With food

Effect of Food No clinically relevant differences in brensocatib pharmacokinetics were observed following administration of brensocatib with a high-fat meal (990 calories, 52% fat).

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-16

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

Every strength and form (2)

Details

Made by	Insmed Netherlands B.V.
Active substance	Brensocatib
Used in	Breathing, airways, allergies and cough
Classification	R03 · Breathing, airways, allergies and cough
Additional monitoring ▼	Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on	2025-11-18
Last updated by the regulator	2026-09-16
EMA product number	EMEA/H/C/005820

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Report wrong or outdated information on this page